Trial Profile
Intraperitoneal application of the trifunctional monoclonal antibody catumaxomab in outpatients with malignant ascites related to various epithelial tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2015
Price :
$35
*
At a glance
- Drugs Catumaxomab (Primary)
- Indications Malignant ascites
- Focus Therapeutic Use
- 21 Sep 2015 New trial record